Skip to main content
Top
Published in: Respiratory Research 1/2007

Open Access 01-12-2007 | Research

Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma

Authors: Catherine M Houghton, Naomi Lawson, Zoe L Borrill, Claire L Wixon, Sally Yoxall, Stephen J Langley, Ashley Woodcock, Dave Singh

Published in: Respiratory Research | Issue 1/2007

Login to get access

Abstract

Background

This study compared the effect of inhaled fluticasone propionate (FP) with the combination of salmeterol/fluticasone propionate (SFC) on lung function parameters in patients with mild asthma.

Methods

Adult patients with mild persistent asthma (≥ 80% predicted FEV1) receiving 200–500 μg of BDP or equivalent were randomised to receive either FP 100 μg or SFC 50/100 μg twice daily from a Diskus® inhaler for four weeks. The primary outcome was the change from baseline in airway resistance (sRaw) at 12 hrs post dose measured by whole body plethysmography. Impulse oscillometry and spirometry were also performed.

Results

A comparison of the geometric mean sRaw at 12 hrs post dose in the SFC group to the FP group gave a ratio of 0.76 (0.66 – 0.89, p < 0.001) at week 2 and 0.81 (0.71 – 0.94, p = 0.006) at week 4. Similarly, significant results in favour of SFC for oscillometry measurements of resistance and reactance were observed. FEV1 was also significantly superior at week 2 in the SFC group (mean difference 0.16L, 95% CI; 0.03 – 0.28, p = 0.015), but not at week 4 (mean difference 0.17L, 95% CI -0.01 – 0.34, p = 0.060).

Conclusion

SFC is superior to FP in reducing airway resistance in mild asthmatics with near normal FEV1 values. This study provides evidence that changes in pulmonary function in patients with mild asthma are detected more sensitively by plethysmography compared to spirometry

Trial registration number

NCT00370591.
Literature
1.
go back to reference Houghton CM, Woodcock AA, Singh D: A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol 2004, 58:134–141.CrossRefPubMedPubMedCentral Houghton CM, Woodcock AA, Singh D: A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol 2004, 58:134–141.CrossRefPubMedPubMedCentral
2.
go back to reference Houghton CM, Woodcock AA, Singh D: A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. Br J Clin Pharmacol 2005, 59:152–159.CrossRefPubMedPubMedCentral Houghton CM, Woodcock AA, Singh D: A comparison of plethysmography, spirometry and oscillometry for assessing the pulmonary effects of inhaled ipratropium bromide in healthy subjects and patients with asthma. Br J Clin Pharmacol 2005, 59:152–159.CrossRefPubMedPubMedCentral
4.
6.
go back to reference Hellinckx J, Cauberghs M, de Boeck K, Demedts M: Evaluation of impulse oscillation system: comparison with forced oscillation technique and body plethysmography. Eur Respir J 2001, 18:564–570.CrossRefPubMed Hellinckx J, Cauberghs M, de Boeck K, Demedts M: Evaluation of impulse oscillation system: comparison with forced oscillation technique and body plethysmography. Eur Respir J 2001, 18:564–570.CrossRefPubMed
7.
go back to reference van Noord JA, Schreurs AJ, Mol SJ, Mulder PG: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999, 54:207–212.CrossRefPubMedPubMedCentral van Noord JA, Schreurs AJ, Mol SJ, Mulder PG: Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma. Thorax 1999, 54:207–212.CrossRefPubMedPubMedCentral
8.
go back to reference Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH: Addition of salmeterol to fluticasone propionate treatment in moderate to severe asthma. Respir Med 2003, 97:555–562.CrossRefPubMed Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH: Addition of salmeterol to fluticasone propionate treatment in moderate to severe asthma. Respir Med 2003, 97:555–562.CrossRefPubMed
9.
go back to reference Matz J, Emmett A, Rickard K, Kalberg C: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001,107(Suppl 5):783–789.CrossRefPubMed Matz J, Emmett A, Rickard K, Kalberg C: Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: An analysis of asthma exacerbations. J Allergy Clin Immunol 2001,107(Suppl 5):783–789.CrossRefPubMed
10.
go back to reference Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. In NHLBI Workshop Report. National Institutes for Health National Heart, Lung and Blood Institute; 2002. NIH Publication Number 02–3659. Global Initiative for Asthma (GINA): Global strategy for asthma management and prevention. In NHLBI Workshop Report. National Institutes for Health National Heart, Lung and Blood Institute; 2002. NIH Publication Number 02–3659.
11.
go back to reference Pellegrino R, Sterk PJ, Sont JK, Brusasco V: Assessing the effect of deep inhalation on airway calibre: a novel approach to lung function in bronchial asthma and COPD. Eur Respir J 1998, 12:1219–1227.CrossRefPubMed Pellegrino R, Sterk PJ, Sont JK, Brusasco V: Assessing the effect of deep inhalation on airway calibre: a novel approach to lung function in bronchial asthma and COPD. Eur Respir J 1998, 12:1219–1227.CrossRefPubMed
12.
go back to reference Langley SJ, Holden J, Derham A, Hedgeland P, Sharma RK, Woodcock A: Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness. Chest 2002, 122:806–811.CrossRefPubMed Langley SJ, Holden J, Derham A, Hedgeland P, Sharma RK, Woodcock A: Fluticasone propionate via the Diskhaler or hydrofluoroalkane-134a metered-dose inhaler on methacholine-induced airway hyperresponsiveness. Chest 2002, 122:806–811.CrossRefPubMed
13.
go back to reference van Noord JA, Smeets JJ, Raaijimaker JAM, Bommer AM, Maesen FP: Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996, 9:1684–1688.CrossRefPubMed van Noord JA, Smeets JJ, Raaijimaker JAM, Bommer AM, Maesen FP: Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action. Eur Respir J 1996, 9:1684–1688.CrossRefPubMed
14.
go back to reference Palmqvist M, Perrson G, Lazer L, Rosenborg J, Larsson P, Lotvall J: In haled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997, 10:2484–2489.CrossRefPubMed Palmqvist M, Perrson G, Lazer L, Rosenborg J, Larsson P, Lotvall J: In haled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997, 10:2484–2489.CrossRefPubMed
15.
go back to reference Van Noord JA, Smeets J, Clement J, van de Woestijne KP, Demedts M: Assessment of reversibility of airflow obstruction. Am J Respir Crit Care Med 1994, 150:551–554.CrossRefPubMed Van Noord JA, Smeets J, Clement J, van de Woestijne KP, Demedts M: Assessment of reversibility of airflow obstruction. Am J Respir Crit Care Med 1994, 150:551–554.CrossRefPubMed
16.
go back to reference Martin RJ: Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002,109(Suppl 2):S447-S460.CrossRefPubMed Martin RJ: Therapeutic significance of distal airway inflammation in asthma. J Allergy Clin Immunol 2002,109(Suppl 2):S447-S460.CrossRefPubMed
17.
go back to reference Currie GP, Stenback S, Lipworth BJ: Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003, 56:11–17.CrossRefPubMedPubMedCentral Currie GP, Stenback S, Lipworth BJ: Effects of fluticasone vs. fluticasone/salmeterol on airway calibre and airway hyperresponsiveness in mild persistent asthma. Br J Clin Pharmacol 2003, 56:11–17.CrossRefPubMedPubMedCentral
18.
go back to reference Mead J: Contribution of compliance of airways to frequency-dependent behaviour of lungs. J Appl Physiol 1969, 26:670–3.PubMed Mead J: Contribution of compliance of airways to frequency-dependent behaviour of lungs. J Appl Physiol 1969, 26:670–3.PubMed
19.
go back to reference De La Hoz RE, Berger KI, Klugh TT, Friedman-Jimenez G, Goldring RM: Frequency depndance of compliance in the evaluation of patients with unexplained respiratory symptoms. Respir Med 2000, 94:221–7.CrossRefPubMed De La Hoz RE, Berger KI, Klugh TT, Friedman-Jimenez G, Goldring RM: Frequency depndance of compliance in the evaluation of patients with unexplained respiratory symptoms. Respir Med 2000, 94:221–7.CrossRefPubMed
20.
go back to reference van Noord JA, Clement J, van de Woestijne KP, Demedts M: Total respiratory resistance and reactance in patients with asthma, chronic bronchitis, and emphysema. Am RevRespir Dis 1991,143(5 Pt 1):922–927.CrossRef van Noord JA, Clement J, van de Woestijne KP, Demedts M: Total respiratory resistance and reactance in patients with asthma, chronic bronchitis, and emphysema. Am RevRespir Dis 1991,143(5 Pt 1):922–927.CrossRef
21.
go back to reference Bouaziz N, Beyaert C, Gauthier R, Monin P, Peslin R, Marchal F: Respiratory system reactance as an indicator of the intrathoracic airway response to methacholine in children. Pediatr pulmonol 1996, 22:7–13.CrossRefPubMed Bouaziz N, Beyaert C, Gauthier R, Monin P, Peslin R, Marchal F: Respiratory system reactance as an indicator of the intrathoracic airway response to methacholine in children. Pediatr pulmonol 1996, 22:7–13.CrossRefPubMed
22.
go back to reference Skloot G, Goldman M, Fishler D, Goldman C, Schechter C, Levin S, Teirstein A: Respiratory assessment and physiological symptoms of ironworkers at the world trade center disaster site. Chest 2004, 125:1248–55.CrossRefPubMed Skloot G, Goldman M, Fishler D, Goldman C, Schechter C, Levin S, Teirstein A: Respiratory assessment and physiological symptoms of ironworkers at the world trade center disaster site. Chest 2004, 125:1248–55.CrossRefPubMed
23.
go back to reference Cheung D, Timmers MC, Zwiderman AH, Bel EH, Dijkman JH, Sterk PJ: Long-term effects of a long-acting beta2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992, 327:1198–1203.CrossRefPubMed Cheung D, Timmers MC, Zwiderman AH, Bel EH, Dijkman JH, Sterk PJ: Long-term effects of a long-acting beta2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992, 327:1198–1203.CrossRefPubMed
24.
go back to reference Britton MG, Earnshaw JS, Palmer JBD: A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J 1992, 5:1062–67.PubMed Britton MG, Earnshaw JS, Palmer JBD: A twelve month comparison of salmeterol and salbutamol in asthmatic patients. Eur Respir J 1992, 5:1062–67.PubMed
25.
go back to reference Lundback B, Rawlinson DW, Palmer JBD: Twelve month comparison of salmeterol with salbutamol as dry powder formulations in asthmatic patients. Thorax 1993, 48:148–53.CrossRefPubMedPubMedCentral Lundback B, Rawlinson DW, Palmer JBD: Twelve month comparison of salmeterol with salbutamol as dry powder formulations in asthmatic patients. Thorax 1993, 48:148–53.CrossRefPubMedPubMedCentral
26.
go back to reference Lundback B, Ronmark E, Lindberg A, Jonsson AC, Levsson LG, Petavy F, James M: Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006, 100:2–10.CrossRefPubMed Lundback B, Ronmark E, Lindberg A, Jonsson AC, Levsson LG, Petavy F, James M: Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate. Respir Med 2006, 100:2–10.CrossRefPubMed
27.
go back to reference O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tatteresfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001, 164:1392–1397.CrossRefPubMed O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tatteresfield A: Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001, 164:1392–1397.CrossRefPubMed
28.
go back to reference Zeiger RS, Bird SR, Kaplan MS, Pearlman DS, Schatz M, Bird S, Hustad C, Edelman J: Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005, 118:649–647.CrossRefPubMed Zeiger RS, Bird SR, Kaplan MS, Pearlman DS, Schatz M, Bird S, Hustad C, Edelman J: Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005, 118:649–647.CrossRefPubMed
Metadata
Title
Comparison of the effects of salmeterol/fluticasone propionate with fluticasone propionate on airway physiology in adults with mild persistent asthma
Authors
Catherine M Houghton
Naomi Lawson
Zoe L Borrill
Claire L Wixon
Sally Yoxall
Stephen J Langley
Ashley Woodcock
Dave Singh
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2007
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/1465-9921-8-52

Other articles of this Issue 1/2007

Respiratory Research 1/2007 Go to the issue